ARVN (Arvinas) Short Percentage of Float


ARVN Arvinas Inc ARVN
66 GF Score
Price $8.37
GF Value $11.82
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Arvinas Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ARVN vs ZURA, KYTX, CBIO: Short Percentage of Float Comparison

For the Biotechnology subindustry, Arvinas's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arvinas Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arvinas's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Arvinas's Short Percentage of Float falls into.


ARVN
66GF Score
Arvinas Inc ARVN
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arvinas (ARVN) Overvalued in 2026?

Based on GuruFocus' analysis, Arvinas stock appears to be undervalued. The current stock price of $8.37 is trading 29.2% below its estimated GF Value™ of $11.82. GuruFocus considers Arvinas to be Modestly Undervalued.

Key valuation signals for ARVN:

  • Short Percentage of Float:
  • GF Value™: $11.82 vs. price of $8.37 (29.2% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the ARVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arvinas Business Description

Address 395 Winchester Avenue, 5 Science Park, New Haven, CT, USA, 06511
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
66GF Score

Get the complete analysis for ARVN

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.37
Price
$11.82
GF Value